Welcome to our dedicated page for Allakos SEC filings (Ticker: ALLK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Access archived SEC filings for Allakos Inc (ALLK), a former biotechnology company focused on developing monoclonal antibody therapies. These historical documents—including 10-K annual reports, 10-Q quarterly filings, and Form 4 insider transactions—provide a record of the company's financial history and regulatory disclosures before its acquisition.
Allakos's SEC filings documented the financial realities of research-stage biotechnology development. The 10-K annual reports detailed the company's clinical trial expenditures, cash runway, and risk factors specific to drug development companies without approved products. Quarterly 10-Q filings tracked research and development spending across clinical programs, providing transparency into how the company allocated resources between clinical trials, regulatory activities, and corporate operations. For biotechnology investors, these financial statements reveal the burn rate and funding requirements that characterize pre-revenue drug developers.
Form 4 insider transaction filings showed executive and director stock purchases and sales, offering insight into management confidence during various stages of clinical development. The 8-K material event reports documented significant milestones such as clinical trial initiations, restructuring decisions, and ultimately the acquisition agreement. These regulatory filings collectively tell the story of Allakos's journey as a publicly traded biotechnology company pursuing antibody-based therapeutics.
Our AI-powered summaries help you quickly understand complex biotechnology accounting, clinical trial cost structures, and regulatory terminology without reading through hundreds of pages of technical documentation. Review these historical filings to understand the financial trajectory and regulatory compliance of a clinical-stage biotech company.
Schedule 13G/A filed on behalf of Beryl Capital entities and David A. Witkin reports no beneficial ownership of Allakos Inc. The filing, covering Common Stock (CUSIP 01671P100) and referencing the event date 06/30/2025, lists Beryl Capital Management LLC, Beryl Capital Management LP, Beryl Capital Partners II LP and David A. Witkin as reporting persons. Each reporting person disclaims beneficial ownership and the filing shows an aggregate amount of 0 shares (0%) for all listed filers. The document includes the issuer address, signatures dated 07/31/2025 by Andrew Nelson and David A. Witkin, a certification that the securities were acquired and held in the ordinary course of business and not to influence control, and Exhibit 99.1 (Agreement Regarding Joint Filing).
Three reporting persons filed a Schedule 13G/A for Allakos Inc. (Common Stock). The filers—Deep Track Capital, LP; Deep Track Biotechnology Master Fund, Ltd.; and David Kroin—report zero shares beneficially owned and 0.00% ownership of the class. The statement shows no sole or shared voting or dispositive power attributed to any reporting person.
The calculation of the percentage is based on the issuer's reported share count of 90,376,972 common shares outstanding. The filing includes a joint filing statement where the undersigned agree to file future amendments on behalf of each other and confirm responsibility for their respective disclosures.
FAQ
What is the current stock price of Allakos (ALLK)?
What is the market cap of Allakos (ALLK)?
